IGF::OT::IGF Retrospective Tumor Characterization Analysis

分子图谱预测治疗反应(MP2PRT)计划将通过利用从NCI国家临床试验网络(NCTN)计划和/或NCI社区肿瘤学研究计划(NCORP)进行并存储在其关联的生物样本库中的已完成试验(具有可用的结果)中收集的生物样本来实施蓝丝带小组的建议。从NCTN/NCORP小组征集的具有生物样品档案的适当研究项目将在NCI指定的多学科审查程序下，在本任务单的支持下被选择用于分子表征。任务单将支持对选定的NCTN或NCORP试验中存档的生物标本(例如肿瘤组织/正常组织、全血、血浆、血清)进行分子表征的综合方法，利用包括预测和预后建模在内的试验结果数据对分子表征数据进行综合分析，并通过将结果存放在NCI基因组数据共用数据库中来提供结果共享(以及在适当的情况下让适当的NCTN/NCORP小组将临床试验数据存放在NCTN/NCORP数据档案库中)。

The Molecular Profiling to Predict Response to Treatment (MP2PRT) initiative will implement the Blue-Ribbon Panel’s recommendation by leveraging biospecimens collected from completed trials (with available outcome results) that were conducted by the NCI National Clinical Trials Network (NCTN) Program and/or the NCI Community Oncology Research Program (NCORP) and stored in their associated biospecimen repositories. Appropriate research projects solicited from the NCTN/NCORP Groups with archived biospecimens will be selected for molecular characterization under an NCI-designated, multidisciplinary review process with support from this Task Order. The Task Order will support an integrated approach to the molecular characterization of the archived biospecimens (e.g., tumor tissue/normal tissue, whole blood, plasma, serum) from the selected NCTN or NCORP trials, the comprehensive analysis of the molecular characterization data with trial outcome data including predictive and prognostic modeling, and the provision of data sharing of results by depositing the results in the NCI Genomic Data Commons (as well as having the appropriate NCTN/NCORP Group deposit the clinical trial data in the NCTN/NCORP Data Archive, if appropriate).